Man Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT)

Man Group plc bought a new stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 86,640 shares of the company's stock, valued at approximately $425,000. Man Group plc owned 0.15% of Rezolute at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of RZLT. JPMorgan Chase & Co. acquired a new stake in shares of Rezolute during the third quarter worth about $42,000. Alpine Global Management LLC purchased a new position in shares of Rezolute in the 4th quarter valued at approximately $54,000. Charles Schwab Investment Management Inc. raised its stake in shares of Rezolute by 65.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after purchasing an additional 9,000 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in shares of Rezolute during the fourth quarter worth $154,000. Finally, Balyasny Asset Management L.P. purchased a new position in Rezolute in the 4th quarter valued at $168,000. Institutional investors and hedge funds own 82.97% of the company's stock.

Insider Activity

In related news, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction dated Thursday, March 27th. The stock was bought at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the transaction, the chief executive officer now directly owns 224,119 shares of the company's stock, valued at approximately $638,739.15. This represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Daron Evans purchased 10,000 shares of Rezolute stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the transaction, the chief financial officer now directly owns 237,900 shares in the company, valued at $687,531. This represents a 4.39% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 29,060 shares of company stock valued at $83,694 in the last ninety days. Company insiders own 18.39% of the company's stock.

Rezolute Trading Down 1.7%

Shares of NASDAQ RZLT traded down $0.07 during midday trading on Friday, reaching $4.09. 767,274 shares of the stock were exchanged, compared to its average volume of 590,560. The company has a market capitalization of $349.77 million, a P/E ratio of -3.35 and a beta of 1.01. The stock has a 50 day moving average price of $3.36 and a 200-day moving average price of $4.18. Rezolute, Inc. has a 52-week low of $2.22 and a 52-week high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). On average, analysts forecast that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on RZLT shares. JMP Securities lifted their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a report on Thursday, February 13th. Wall Street Zen downgraded Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Wedbush reiterated an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a research report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $12.14.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.